Description:
This is an open-label, multicentre phase I/II trial of the pharmacokinetics, safety and acceptability of novel formulations of moxifloxacin and clofazimine in children routinely treated for RR-TB.
Start Date: March 21, 2019
Eligibility:
Thirty-six children were enrolled in South Africa, India, and the Philippines.
It included HIV-infected and -uninfected children from birth to < 15 years of age.
Who had either clinically diagnosed or confirmed RR-TB and had started RR-TB treatment in routine care.
To Participate in the study kindly reach us via: